{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT01202942: Not Applicable Interventional Completed Cigarette Smoking
(2007)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04023526: Phase 2 Interventional Active, not recruiting Leukemia, Myeloid, Acute
(2019)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT02657447: Phase 1 Interventional Withdrawn Non-Hodgkin Lymphoma
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03562637: Phase 3 Interventional Recruiting Triple Negative Breast Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:insulin defalan (bovine) [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:insulin defalan (porcine) [INN]
Source URL:
Class:
PROTEIN
Insulin Defalan (Porcine) is an insulin analog patented by Hoechst A.-G. and studied as a potentival treatment of type 1 diabetes mellitus. The primary activity of insulin, including Insulin Defalan, is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin Defalan (Porcine) differs from porcine insulin in that phenylalanine is removed from C-terminus of the B-chain.
Class:
PROTEIN
Status:
Investigational
Source:
NCT03539536: Phase 2 Interventional Active, not recruiting Non-small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
